| Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma. | |
| | |
MedLine Citation:
|
PMID: 23151824 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To evaluate tumor response by means of volumetric assessment, survival, and changes in patient symptoms after the treatment of unresectable and/or recurrent pleural mesothelioma by using regional nonselective transarterial chemoperfusion as a palliative treatment option. MATERIALS AND METHODS: This retrospective study was approved by the hospital ethical committee, and all patients signed an informed consent prior to treatment. Thirty-nine patients (mean age, 64.0 years; 10 women and 29 men) with unresectable pleural mesothelioma were treated with repetitive transarterial chemoperfusion between March 2007 and March 2010, with a mean of 2.9 sessions per patient at 4-week intervals. Transarterial chemoperfusion was performed by using mitomycin C, cisplatin, and gemcitabine. Computed tomography findings and patient symptoms were evaluated. Tumor response was evaluated by using Response Evaluation Criteria in Solid Tumors guidelines, and survival was assessed with the Kaplan-Meier method. The change in volume for the partial-response group was tested by using the Wilcoxon signed-rank test. RESULTS: In 36% of treated tumors (14 of 39), partial response was achieved, and tumor volume decreased from a mean value ± standard deviation of 839.6 mL ± 590.3 (range, 3.9-1972.2 mL) to 137 mL ± 399.8 (range, 0.88-1131.4; P = .00012). In 49% of tumors (19 of 39), stable disease was noted. In 15% of tumors (six of 39), progressive disease was seen. Mean specific growth rate of the tumor was 0.00158% per day. The mean survival time was 14.2 months (range, 2.1-33.1 months) from the start of treatment. For patients with tumors that responded to treatment, mean survival time was 15 months (range, 4.5-33.1 months). Mean time to disease progression was 2.6 months for all tumors, 1.5 months for stable disease, and 1.3 months for progressive disease. CONCLUSION: Transarterial chemoperfusion may have the potential to yield positive results and response in the treatment of recurrent and/or unresectable pleural mesothelioma. © RSNA, 2012. |
| | |
Authors:
|
Thomas J Vogl; Sebastian Lindemayr; Nagy N N Naguib; Jessen Gurung; Nour-Eldin A Nour-Eldin; Stephan Zangos; Emmanuel C Mbalisike |
Related Documents
:
|
8107654 - Catecholamine metabolites in ganglioneuroma. 21481014 - Clinical significance of immediate urine cytology after transurethral resection of blad... 23335424 - Quantification of microvascular cerebral blood flux and late-stage tumor compartmentali... 23564814 - He4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovar... 6683794 - Intracerebral growth of a human glioma tumor line in athymic mice and treatment with pr... 11175354 - A novel role for irf-1 as a suppressor of apoptosis. |
Publication Detail:
|
Type: Journal Article Date: 2012-11-14 |
Journal Detail:
|
Title: Radiology Volume: 266 ISSN: 1527-1315 ISO Abbreviation: Radiology Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-01-30 Completed Date: 2013-04-05 Revised Date: 2013-06-03 |
Medline Journal Info:
|
Nlm Unique ID: 0401260 Medline TA: Radiology Country: United States |
Other Details:
|
Languages: eng Pagination: 649-56 Citation Subset: AIM; IM |
Affiliation:
|
Institute for Diagnostic and Interventional Radiology, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. T.Vogl@em.uni-frankfurt.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols
/
therapeutic use* Cisplatin / administration & dosage Deoxycytidine / administration & dosage, analogs & derivatives Disease Progression Female Humans Infusions, Intra-Arterial Male Mesothelioma / drug therapy* Middle Aged Mitomycin / administration & dosage Pain Measurement Palliative Care* Pleural Neoplasms / drug therapy* Questionnaires Retrospective Studies Statistics, Nonparametric Tomography, X-Ray Computed Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
15663-27-1/Cisplatin; 50-07-7/Mitomycin; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dynamic Contrast-enhanced MR Imaging of Carotid Atherosclerotic Plaque: Model Selection, Reproducibi...
Next Document: Regional and global biventricular function in pulmonary arterial hypertension: a cardiac MR imaging ...